A real-world study to determine safety and efficacy of dual DTG based regimens 3TC/DTG and RPV/DTG in people living with HIV
Latest Information Update: 19 Dec 2022
At a glance
- Drugs Dolutegravir/lamivudine (Primary) ; Dolutegravir/rilpivirine (Primary)
- Indications HIV infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms SCOLTA
Most Recent Events
- 19 Dec 2022 New trial record
- 26 Oct 2022 Results presented at the 16th International Congress on Drug Therapy and HIV Infection